Gionata Fiorino Selected Research

Biosimilar Pharmaceuticals

1/2022	Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study.
10/2021	Adalimumab biosimilar in inflammatory bowel disease.
10/2020	Biosimilar switching in inflammatory bowel disease: from evidence to clinical practice.
10/2019	Biosimilars of adalimumab: the upcoming challenge in IBD.
1/2019	Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that?
1/2019	Anti-TNF Biosimilars in Inflammatory Bowel Disease: Searching the Proper Patient's Profile.
1/2019	Effectiveness of Infliximab Biosimilar in Crohn's Disease: A Dime, A Dozen.
1/2019	Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD).
1/2018	Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease.
11/2017	Biosimilar Drugs for Inflammatory Bowel Disease: Is Similar Good Enough?

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Gionata Fiorino Research Topics

Disease

53	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 10/2022 - 01/2011
44	Ulcerative Colitis 10/2022 - 01/2011
40	Crohn Disease (Crohn's Disease) 05/2022 - 01/2011
14	Inflammation (Inflammations) 02/2022 - 07/2010
8	Infections 07/2021 - 10/2016
7	Neoplasms (Cancer) 01/2022 - 11/2013
6	Necrosis 01/2022 - 06/2012
6	COVID-19 12/2021 - 01/2020
4	Pathologic Constriction (Stenosis) 01/2022 - 09/2012
4	Colitis 11/2017 - 09/2011
3	Anemia 04/2022 - 01/2014
3	Fistula 01/2022 - 09/2012
3	Fibrosis (Cirrhosis) 01/2021 - 11/2019
3	Pneumonia (Pneumonitis) 10/2020 - 06/2012
3	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2019 - 01/2014
3	Rheumatoid Arthritis 12/2017 - 06/2014
2	Thrombosis (Thrombus) 08/2022 - 01/2021
2	Abscess 01/2022 - 09/2012
2	Opportunistic Infections (Opportunistic Infection) 07/2021 - 10/2016
2	Disease Progression 05/2021 - 12/2017
2	Psoriatic Arthritis 01/2019 - 07/2014
1	Fatigue 04/2022
1	Iron Deficiencies 04/2022
1	Avitaminosis (Vitamin Deficiency) 04/2022
1	Virus Diseases (Viral Diseases) 07/2021
1	Sclerosing Cholangitis 01/2021
1	Toxic Megacolon 01/2021
1	Hemorrhage 01/2021
1	Colorectal Neoplasms (Colorectal Cancer) 12/2020
1	Sneezing 09/2020
1	Venous Thromboembolism 01/2020
1	Idiopathic Pulmonary Fibrosis 11/2019
1	Proctitis 11/2018
1	Infertility (Sterility) 03/2018

Drug/Important Bio-Agent (IBA)

21	Infliximab (Remicade)FDA Link 04/2022 - 01/2011
18	Biosimilar PharmaceuticalsIBA 01/2022 - 06/2014
11	Biological ProductsIBA 04/2022 - 05/2014
11	Adalimumab (Humira)FDA Link 04/2022 - 01/2011
10	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2022 - 04/2011
8	vedolizumabIBA 04/2022 - 12/2015
7	Monoclonal AntibodiesIBA 01/2021 - 01/2011
7	CytokinesIBA 01/2020 - 07/2010
6	Ustekinumab (CNTO 1275)FDA Link 04/2022 - 02/2018
6	Adrenal Cortex Hormones (Corticosteroids)IBA 02/2022 - 01/2012
5	Janus Kinase InhibitorsIBA 02/2022 - 01/2018
5	SteroidsIBA 01/2021 - 04/2013
4	tofacitinibIBA 04/2022 - 01/2019
4	Interleukin-12 (IL 12)IBA 01/2021 - 01/2015
3	Leukocyte L1 Antigen Complex (Calgranulin)IBA 10/2022 - 12/2017
3	IronIBA 04/2022 - 01/2014
3	golimumab FDA Link 04/2022 - 01/2019
3	CT-P13IBA 01/2022 - 01/2017
3	Biomarkers (Surrogate Marker)IBA 01/2021 - 12/2017
3	Mesalamine (Mesalazine)FDA LinkGeneric 09/2020 - 01/2017
3	Interleukin-23 (Interleukin 23)IBA 01/2020 - 01/2017
3	Immunologic Factors (Immunomodulators)IBA 06/2019 - 04/2011
3	IntegrinsIBA 01/2019 - 07/2010
2	VaccinesIBA 08/2022 - 04/2011
2	Pharmaceutical PreparationsIBA 01/2020 - 07/2010
2	Immunosuppressive Agents (Immunosuppressants)IBA 01/2020 - 07/2014
2	Antifibrotic AgentsIBA 11/2019 - 01/2019
2	AntibodiesIBA 01/2019 - 01/2018
2	Methotrexate (Mexate)FDA LinkGeneric 03/2018 - 07/2016
2	InterleukinsIBA 02/2018 - 01/2017
2	Janus KinasesIBA 01/2018 - 01/2015
2	Azathioprine (Imuran)FDA LinkGeneric 11/2016 - 08/2014
2	etrolizumabIBA 07/2016 - 12/2014
1	Coloring Agents (Dyes)IBA 01/2022
1	ozanimodIBA 01/2022
1	Protective AgentsIBA 01/2021
1	C-Reactive ProteinIBA 12/2020
1	Soaps (Soap)IBA 09/2020
1	Therapeutic UsesIBA 12/2019
1	Protein Kinases (Protein Kinase)IBA 11/2019
1	Proteins (Proteins, Gene)FDA Link 11/2019
1	GadoliniumIBA 11/2019
1	Budesonide (Pulmicort)FDA LinkGeneric 11/2019
1	nintedanibIBA 11/2019
1	pirfenidoneIBA 11/2019
1	Bile Acids and Salts (Bile Acids)IBA 01/2019
1	ontamalimabIBA 07/2018
1	Tumor Necrosis FactorsIBA 07/2018

Therapy/Procedure

44	Therapeutics 04/2022 - 04/2011
8	Biological Therapy 05/2022 - 04/2011
3	Remission Induction 11/2019 - 04/2014
2	Drug Therapy (Chemotherapy) 01/2021 - 04/2017
1	Lasers (Laser) 02/2022
1	Transjugular Intrahepatic Portasystemic Shunt 07/2021
1	Liver Transplantation 01/2021
1	Lung Transplantation 05/2020
1	Continuous Positive Airway Pressure 01/2020
1	Respiratory Therapy (Therapy, Respiratory) 01/2020
1	Artificial Respiration (Mechanical Ventilation) 01/2020
1	Personal Protective Equipment 01/2020
1	Operative Surgical Procedures 11/2019
1	Polypharmacy 11/2019
1	Aftercare (After-Treatment) 01/2019
1	Combined Modality Therapy 11/2018
1	Proctectomy 11/2018
1	Restorative Proctocolectomy 03/2018